Cargando…
Filgrastim, fibrinolysis, and neovascularization
Segmental recanalization of chronically occluded arteries was observed in patients with chronic limb‐threatening ischemia (CLTI) treated with Filgrastim, a granulocyte colony stimulating factor, every 72 h for up to a month, and an infra‐geniculate programmed compression pump (PCP) for 3 h daily. Mo...
Autores principales: | Eton, Darwin, Zhou, Guolin, He, Tong‐Chuan, Bartholomew, Amelia, Patil, Rachana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302657/ https://www.ncbi.nlm.nih.gov/pubmed/35175691 http://dx.doi.org/10.1002/term.3284 |
Ejemplares similares
-
Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021) -
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013) -
Bronchoalveolar Activation of Coagulation and Inhibition of Fibrinolysis during Ventilator-Associated Lung Injury
por: Schultz, M. J., et al.
Publicado: (2012) -
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015) -
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
por: Hegg, Roberto, et al.
Publicado: (2016)